Related Experiment Video

Updated: Mar 30, 2026

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
08:46

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

10.3K

Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells

Erica Gentilin1, Carmelina Di Pasquale2, Teresa Gagliano2

  • 1Section of Endocrinology & Internal Medicine, Dept. of Medical Sciences, University of Ferrara, Italy; Laboratorio in rete del Tecnopolo "Tecnologie delle terapie avanzate" (LTTA) of the University of Ferrara, Italy.

Molecular and Cellular Endocrinology
|November 3, 2015
PubMed

Insights

Protein Kinase C Delta (PRKCD) restrains pituitary tumor growth. Silencing PRKCD in corticotroph adenomas increases cell viability and aggressiveness, suggesting PRKCD as a potential therapeutic target.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Background:

  • Protein Kinase C Delta (PRKCD) is implicated in disrupted pathways within corticotroph adenomas.
  • Low PRKCD expression in human corticotroph adenomas suggests a role in cell cycle control.
  • Further research is needed to understand PRKCD's function in pituitary cell growth regulation.

Purpose of the Study:

  • To investigate the role of PRKCD in modulating corticotroph adenoma cell behavior.
  • To assess the impact of PRKCD silencing on cell viability, hormone expression, and protein profiles.
  • To determine if PRKCD influences aggressive tumor characteristics.

Main Methods:

  • PRKCD was silenced in AtT-20/D16v-F2 corticotroph adenoma cells.
  • Cell viability, hormone expression, and protein expression were analyzed.
  • Changes in cell morphology and adhesion molecule expression were evaluated.

Main Results:

  • PRKCD silencing led to increased cell viability and enhanced hormone expression.
  • Morphological changes indicated deregulation of adhesion molecules.
  • Epithelial Growth Factor Receptor (EGFR) expression increased, correlating with aggressive behavior and sensitivity to anti-EGFR therapies.

Conclusions:

  • PRKCD appears to inhibit aggressive behavior in corticotroph adenoma cells.
  • PRKCD warrants further investigation as a potential molecular target for corticotroph adenoma treatment.
  • Targeting PRKCD may offer a novel therapeutic strategy for pituitary tumors.
Keywords:
ACTHEpithelial growth factor receptorPituitaryProtein Kinase C Delta

More Related Videos

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.7K
Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death09:18

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death

Published on: December 27, 2016

9.2K

Related Concept Videos

GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
8.3K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
9.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K